TY  - JOUR 
AU  - Hernández-García, Susana
AU  - San Segundo, Laura
AU  - González-Méndez, Lorena
AU  - Corchete Sánchez, Luis Antonio
AU  - Misiewicz-Krzeminska, Irena
AU  - Martín-Sánchez, Montserrat
AU  - López-Iglesias, Ana-Alicia
AU  - Algarín, Esperanza Macarena
AU  - Mogollón Arroyo, Pedro
AU  - Díaz-Tejedor, Andrea
AU  - Paíno Gómez, María Teresa
AU  - Tunquist, Brian
AU  - Mateos Manteca, María Victoria
AU  - Gutiérrez Gutiérrez, Norma Carmen
AU  - Díaz-Rodriguez, Elena
AU  - Garayoa Berrueta, Mercedes
AU  - Ocio San Miguel, Enrique M.
PY  - 2017
SN  - Print ISSN  0390-6078
SN  - Online ISSN  1592-8721
UR  - http://hdl.handle.net/10366/135831
AB  - [EN]Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of...
LA  - eng
PB  - Ferrara Storti Foundation
KW  - MEDICINE
KW  - Filanesib
KW  - Kinesin spindle protein inhibitor
KW  - Pomalidomide
KW  - Dexamethasone
KW  - Monopolar spindles
KW  - BAK activation
KW  - Multiple myeloma
TI  - The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
DO  - 10.3324/haematol.2017.168666
ER  -